INHBA

Across TCGA pan-cancer cohorts, INHBA mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated INHBA data layer compared with 27 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher INHBA mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated INHBA expression acts as an unfavorable survival marker.

PDAC, LUAD, and LSCC are the cancer types where INHBA mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.187	0.494	.002	28	view →
LUAD	OS	Tertile	All	0.764	0.950	.006	13	view →
LSCC	OS	Tertile	All	0.728	0.910	.012	7	view →
CCRCC	OS	Median	All	0.332	0.934	.017	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

INHBA–PDAC (DFS)

Open the PDAC breakdown →